Exhibit 99.1 Precigen Reports First Quarter 2024 Financial Results and Business Updates – Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation on June 3 – – Company to host a conference call on June 3 following the PRGN-2012 ASCO presentation to discuss in detail the pivotal study results and provide business updates – – PRGN-2012 rolling BLA submission, under an ac ...